Key Stats for RadNet Stock
- Stock Movement (Recent): -3.51%
- Current Price: $72.58
- Street Target Price: $92.38
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
RadNet, Inc. (RDNT) is maintaining its baseline valuation, with shares trading at $72.58 (down 3.51%) following a highly anticipated earnings release and the announcement of a transformative acquisition.
The national leader in outpatient radiology delivered actual revenue of $547.7 million, outperforming analyst estimates of $515.67 million by a solid 6.21%.
Moreover, operational efficiency also exceeded expectations. RadNet delivered an actual Adjusted EBITDA of $87.7 million, beating the Street estimate of $84.08 million by 4.31%.
However, the primary focus of the management call was not just the financial beat, but the official acquisition of Paris-based AI startup Gleamer, which will be fully integrated into RadNet’s DeepHealth division.
Additionally, Chief Strategy Officer Greg Sorensen highlighted RadNet’s massive physical footprint, over 425 imaging centers, and 26 joint venture partners, as the perfect deployment ground for this new technology.
Sorensen emphasized the scale of the company’s routine imaging workflow, stating that RadNet alone performs about 2 million mammograms and 2.8 million x-rays a year.
Furthermore, DeepHealth President and CEO Kees Wesdorp detailed exactly how the Gleamer acquisition positions the company as the undisputed global leader in AI-powered health informatics.
Wesdorp stated verbatim: “we can now say that we jointly serve over 2,700 customer contracts worldwide. We have a global footprint of 550 employees and teammates. We have increased our clinically validated portfolio with 26 FDA-cleared and 22 CE marked solutions covering over 75 indications.”
The integration of Gleamer is expected to generate $2 million in direct cost savings and drive a $7 million-plus revenue run rate increase through cross-selling and upselling opportunities across the U.S. and EMEA.
See analysts’ growth forecasts and price targets for RadNet stock (It’s free!) >>>
Is RadNet Undervalued Today?
Aggregated analyst data indicate that the market is heavily underestimating the compounding value of the company’s rapidly expanding DeepHealth AI division and its massive physical clinical network.
The consensus Street target price of $92.38 represents an attractive 27.3% potential return from the current $72.58 baseline.
While navigating short-term market dynamics, the operational reality shows a company successfully commercializing artificial intelligence at an unprecedented scale to combat radiologist labor shortages and inconsistent clinical outcomes.
Wesdorp explained exactly how the combined entity will accelerate its financial trajectory in the coming year.
Wesdorp stated verbatim: “if you then look at what we’ve guided on in 2026 as part of our earnings call today, the combination will deliver is guided to deliver EUR 135 million to EUR 145 million in revenue, EUR 120 million to EUR 140 million of ARR, and that implies an 80% to 90% ARR growth.”
Read the full RadNet Transcript on TIKR to see the 2026 product roadmap >>>
Valuation Deep Dive
The TIKR Analyst Breakdown identifies RadNet as a transitioning healthcare infrastructure leader successfully pivoting from purely physical diagnostic centers into a high-margin software and AI powerhouse.
- Street Target Price: $92.38
- Current Price: $72.58
- Target Return: 27.3%
The DeepHealth Commercial Monopoly: RadNet is aggressively positioning itself to own the clinical AI space by vertically integrating its technology development directly with its massive patient volume. The combined Gleamer and DeepHealth entity now boasts over 3,000 healthcare provider locations worldwide, supporting over 50 million imaging studies per year. By merging European CE marks with U.S. FDA clearances, the company has drastically expanded its addressable market.
Explosive Scale and ARR Growth: The commercial engine is operating at peak efficiency. Management highlighted that DeepHealth’s standalone achieved EUR 93 million in 2025 revenue with 35% recurring growth, while Gleamer brings an established track record of 90% annual recurring revenue growth over the past four years. With a clear path to generating EUR 140 million in ARR by the end of 2026, the software division is structurally designed to generate significant long-term flexibility.
Conclusion: A revitalized healthcare giant successfully leveraging its massive clinical network and strategic AI acquisitions to accelerate global diagnostic efficiency. RadNet offers a steady path to long-term appreciation. The path to the $92.38 target is paved by the successful integration of Gleamer, the rollout of automated reporting workflows, and the anticipated 80% to 90% growth in its software subscription revenue.
See what stocks billionaire investors are buying so you can follow the smart money with TIKR.
Should You Invest in RadNet?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up RadNet, and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track RadNet alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
[Analyze RadNet on TIKR Free →]
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
